Caris Life Sciences (CAI) Total Current Liabilities (2024 - 2026)

Caris Life Sciences has reported Total Current Liabilities for 3 years, with the latest figure at $191.4 million in Q2 2026.

• On a quarterly basis, Total Current Liabilities rose 112.28% year-over-year to $191.4 million in Q2 2026; TTM through Jun 2026 was $191.4 million, a 112.28% increase from a year earlier, with the FY2025 full-year figure at $127.1 million, down 23.14% from the prior year.
• Total Current Liabilities was $191.4 million for Q2 2026 at Caris Life Sciences, up from $143.9 million in the prior quarter.
• The five-year high for Total Current Liabilities was $191.4 million in Q2 2026, with the low at $86.0 million in Q3 2025.
• Average Total Current Liabilities over 3 years is $134.0 million, with a median of $135.5 million recorded in 2025.
• The sharpest annual moves came in 2025 and 2026: Total Current Liabilities decreased 23.14% in 2025, then surged 112.28% in 2026.
• Over 3 years, Total Current Liabilities stood at $165.4 million in 2024, then slipped by 23.14% to $127.1 million in 2025, then jumped by 50.57% to $191.4 million in 2026.
• The last three Total Current Liabilities figures came in at $191.4 million (Q2 2026), $143.9 million (Q1 2026), and $127.1 million (Q4 2025), per Business Quant data.